You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 4,943,569


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,943,569
Title: B-lactam compounds
Abstract:Novel .beta.-lactam compounds belonging to carbapenem or penem derivatives useful as antimicrobial agents or intermediates therefor and a process for producing these compounds are disclosed.
Inventor(s): Sunagawa; Makoto (Osaka, JP)
Assignee: Sumitomo Pharmaceuticals Co., Ltd. (Osaka, JP)
Application Number:07/106,036
Patent Claims: 1. A .beta.-lactam compound represented by the formula: ##STR427## wherein R.sub.1 represents a 1-hydroxyethyl group or a 1-hydroxyethyl group in which the hydroxy group is protected with a protecting group for a hydroxy group; R.sub.2 represents a hydrogen atom or a protecting group for an amino group; R.sub.3 represents a hydrogen atom or a protecting group for a carboxyl group; X represents an unsubstituted methylene group and Y represents a group of the formula (2): ##STR428## wherein R.sub.5 and R.sub.6, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in the alkyl moiety thereof, a substituted alkyl group having 1 to 4 carbon atoms wherein said substituent is selected from the group consisting of hydroxyl, di-(C.sub.1 -C.sub.3)-alkylamino or carbamoyl, or R.sub.5 and R.sub.6 are taken together to represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a (C.sub.1 -C.sub.3)alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a 4- to 7-membered cyclic amino group, and a pharmaceutically acceptable salt thereof.

2. A .beta.-lactam compound represented by the formula: ##STR429## wherein R.sub.1 represents a 1-hydroxyethyl group or a 1-hydroxyethyl group in which the hydroxy group is protected with a protecting group for a hydroxy group; R.sub.2 represents a hydrogen atom or a protecting group for an amino group; R.sub.3 represents a hydrogen atom or a protecting group for a carboxyl group; X represents a substituted methylene group of the formula (1): ##STR430## wherein R.sub.4 represents an alkyl group having 1 to 3 carbon atoms; and Y represents a group of the formula (2): ##STR431## wherein R.sub.5 and R.sub.6, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in the alkyl moiety thereof, a substituted alkyl group having 1 to 4 carbon atoms wherein said substituent is selected from the group consisting of hydroxyl, di-(C.sub.1 -C.sub.3)-alkylamino or carbamoyl, or R.sub.5 and R.sub.6 are taken together to represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a (C.sub.1 -C.sub.3)-alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a 4- to 7-membered cyclic amino group, and a pharmaceutically acceptable salt thereof.

3. A compound as claimed in claim 1 or 2, wherein R.sub.1 represents a 1-hydroxyethyl group, R.sub.2 and R.sub.3 each represents a hydrogen atom.

4. A compound as claimed in claim 1 or 2, wherein R.sub.1 represents a 1-hydroxyethyl group, R.sub.2 and R.sub.3 each represents a hydrogen atom, and Y is a group represented by the formula (2-c): ##STR432## wherein R.sub.5-c and R.sub.6-c have either one of the following meanings: (1) R.sub.5-c represents an alkyl group having 1 to 4 carbon atoms which may be substituted with a carbamoyl group, or a hydroxyl group, and R.sub.6-c represents a hydrogen atom or has the same meaning as defined for R.sub.5-c ;

(2) R.sub.5-c and R.sub.6-c jointly represent an alkylene chain to form, together with the adjacent nitrogen atom, an unsubstituted 4- to 6-membered saturated cyclic amino group; and

(3) R.sub.5-c and R.sub.6-c jointly represent an alkylene chain via an oxygen atom or a (C.sub.1 -C.sub.3)alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a 6-membered cyclic amino group.

5. A .beta.-lactam compound of the formula: ##STR433## wherein Y is chosen from the group consisting of ##STR434## and the pharmaceutically acceptable salts thereof.

6. A .beta.-lactam compound of the formula: ##STR435## wherein Y is selected from the group consisting of ##STR436##

7. A compound as claimed in claim 3, wherein Y is represented by the formula: ##STR437##

8. A compound as claimed in claim 2, 3, 4, or 7, wherein X represents ##STR438##

10. (5R)-3-[2-((1-Pyrrolidino)carbonyl)pyr rolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2- carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

11. (5R)-3-[2-((1-Azetidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl )-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

12. (5R)-3-[2-((2-Hydroxyethyl)methylamino carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-3- ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

13. (5R)-3-[2- (1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[ 3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

14. (5R)-3-[2-(1-N-Methyl piperazinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2 ,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

15. (5S)-3-[2-Carbamoylpy rrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2 -carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

16. (5S)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hyd roxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

17. (5S)-3-[2-((1-pyrrolidino)carbonyl)pyrrolidin-4- ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-c arboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

18. (5S)-3-[2-((1-Azatidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hyd roxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

19. (5S)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)p yrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-e ne-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

20. (5S)- 3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl) -1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

21. (5S)-3-[2-(1-N-Methylpiperazinocarbony l)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept- 2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

22. (5S)-3-[2- Carbamoylpyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2, 0]hept-2-ene-7-one-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition for antimicrobial use which comprises as an active ingredient a pharmaceutically effective amount of at least one of the compounds as claimed in claim 1 or claim 2 and at least one pharmaceutically acceptable inert carrier or diluent.

24. A method of treating a bacterial infection comprising administering an effective amount of a compound according to claim 1 or claim 2 as an antimicrobial agent.

25. A (5R)-compound of the compound as claimed in claim 1, 3, or 7, which is represented by the formula: ##STR439##

26. A (5S)-compound of the compound as claimed in claim 2, 3, or 7, which is represented by the formula: ##STR440##

27. A (5R,6S,8R)-compound of the compound as claimed in claim 22.

28. A (5S,6S,8R)-compound of the compound as claimed in claim 27.

29. A (5R,6S,8R)-compound of the compound as claimed in any one of claims 10, 11, 12, 13, 14 or 15.

30. A (5S,6S,8R)-compound of the compound as claimed in any one of claims 13, 17, 18, 19, 20, 21, or 22

31. A (5R,6S,8R,2'S,4'S)-compound of the compound as claimed in claim 22.

32. A (5S,6S,8R,2'S,4'S)-compound of the compound as claimed in claim 31.

33. A (5R,6S,8R,2'S,4'S)-compound of the compound as claimed in any one of claims 10, 11, 12, 13, 14 or 15.

34. A (5S,6S,8R,2'S,4'S)-compound of the compound as claimed in any one of claims 13, 17, 18, 19, 20, 21, or 22.

35. A .beta.-lactam compound of the formula: ##STR441## and the pharmaceutically acceptable salts thereof.

36. A .beta.-lactam compound of the formula: ##STR442## and the pharmaceutically acceptable salts thereof.

37. A .beta.-lactam compound of the formula: ##STR443## wherein Y is chosen from the group consisting of ##STR444## and the pharmaceutically acceptable salt thereof.

38. A (5S)-compound of the compound as claimed in claim 8, which is represented by the formula: ##STR445##

39. A (4R,5S,6S,8R,2'S,4'S)-compound of the compound as claimed in any one of claims 2, 8, 18, 19, 20, 21 or 22.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.